|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute of Mental Health (NIMH) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00109174 |
Purpose
This study will use magnetic resonance spectroscopy (MRS) to measure in the brain the transfer of [13]C as it is naturally metabolized from glucose to specific chemical transmitters. From this method, we can measure the rate of production of an important excitatory neurotransmitter (glutamate) as well as an inhibitory neurotransmitter (GABA)....
| Condition | Intervention |
|---|---|
|
Healthy |
Procedure: Magnetic Resonance Spectroscopy |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | MRS (Magnetic Resonance Spectroscopy) Measurement of Glutamate and GABA Metabolism in Brain |
| Estimated Enrollment: | 90 |
| Study Start Date: | April 2005 |
(13)C is a stable (i.e., non-radioactive) isotope of carbon with a natural abundance of approximately 1%. Following infusion of [(13)C]glucose and/or [(13)C]acetate, in vivo MRS (magnetic resonance spectroscopy) can monitor the rate of flux of the (13)C atom from glucose and/or acetate to glutamate to glutamine. Thus, this procedure can provide measure of glutamate (GLU) and glutamine (GLN) turnover in brain. We have established parameters to obtain these measurements in nonhuman primate brain. The current protocol seeks approval to optimize MRS parameters for human brain using the GE 3T device.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Age: 18-65 years
Diagnosis: Healthy
EXCLUSION CRITERIA:
Abnormal fasting blood glucose level (normal values are 70-115 mg/dL)
Serious medical illness (including diabetes) as determined from H& P or laboratory testing
Prescription psychotropic medication; drug free period must be greater than 3 weeks for anticholinergics and benzodiazepine and greater than 8 weeks for fluoxetine, antipsychotics, anticonvulsants
Claustrophobia
Pregnancy; women with child bearing potential will have pregnancy test to exclude pregnancy
Any condition that increases risk for MRI (e.g., pacemaker, metallic foreign body in the eye, etc.)
Unable to lay on one's back for MRI/MRS scans
Positive HIV test
Contacts and Locations| Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
| Contact: TTY | 1-866-411-1010 |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Sub-Investigator: Patient Recruitment and Public Liaison Office (PRPL) For more information at the NIH Clinical Center contact | |
More Information
| ClinicalTrials.gov Identifier: | NCT00109174 History of Changes |
| Other Study ID Numbers: | 050144, 05-M-0144 |
| Study First Received: | April 22, 2005 |
| Last Updated: | December 24, 2011 |
| Health Authority: | United States: Federal Government |
|
Glutamate Excitatory Amino Acid Neurochemistry GABA Magnetic Resonance Spectroscopy |